KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLoans and Notes ReceivablesLong-Term Debt IssuancesNon-Current ReceivablesReceivables RefundsShares OutstandingShares Repurchased
Ratios

Royalty Pharma (RPRX) Non-Current Receivables (2019 - 2025)

Historic Non-Current Receivables for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $16.2 billion.

  • Royalty Pharma's Non-Current Receivables rose 714.82% to $16.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $16.2 billion, marking a year-over-year increase of 714.82%. This contributed to the annual value of $16.2 billion for FY2025, which is 714.82% up from last year.
  • Royalty Pharma's Non-Current Receivables amounted to $16.2 billion in Q4 2025, which was up 714.82% from $15.8 billion recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Non-Current Receivables ranged from a high of $16.2 billion in Q4 2025 and a low of $12.6 billion during Q1 2021
  • Its 5-year average for Non-Current Receivables is $14.1 billion, with a median of $13.8 billion in 2021.
  • Per our database at Business Quant, Royalty Pharma's Non-Current Receivables soared by 1749.34% in 2021 and then tumbled by 739.76% in 2023.
  • Royalty Pharma's Non-Current Receivables (Quarter) stood at $13.7 billion in 2021, then dropped by 1.64% to $13.5 billion in 2022, then grew by 4.41% to $14.1 billion in 2023, then increased by 7.37% to $15.1 billion in 2024, then rose by 7.15% to $16.2 billion in 2025.
  • Its Non-Current Receivables stands at $16.2 billion for Q4 2025, versus $15.8 billion for Q3 2025 and $15.1 billion for Q2 2025.